Abstract 2934
Background
MicroRNAs are examined for clinical utility in active germ cell malignancies (GCM). miR-371a-3p (miR371) has a very high specificity and high sensitivity for the detection of GCM. However, in teratoma neither tissue nor serum/plasma are miR371 positive. miR375 is overexpressed in teratoma tissue, but detectability in blood and its utility is unknown.
Methods
GCM patients (pts) enrolled from 10-2016 to 03-2019 in the GU biobank program at British Columbia Cancer were analyzed for plasma miR371/miR375 expression by RT-PCR and quantified by ΔΔCT method. Spike-in cel-miR-39-3p, miR-451 and miR-30b-5p were used as quality/internal controls. Sensitivity, specificity, PPV, NPV, AUC of the ROC of miR375 in detecting teratoma were analyzed.
Results
miR375 expression was measured in 69 pts of whom 15 (22%) had pathologically confirmed residual teratoma post-chemotherapy, 4 (6%) residual post-chemotherapy mass without teratoma, 8 (11%) no evidence of residual disease post-chemotherapy, 15 (22%) metastatic seminoma and 27 (39%) CSI with no evidence of tumor. miR375 expression was significantly higher in pts with residual teratoma-post chemotherapy than in non-teratoma (p < 0.0001). Concurrent miR371 and miR375 expression was evaluated in 17 pts with metastatic nonseminoma prior to and post-chemotherapy. miR371 correlated with viable GCM and disappeared after chemotherapy in all but one pt (presenting residual choriocarcinoma). Post-chemotherapy miR375 was unchanged or increased from pre-chemotherapy samples in 85% of pts with pathologically confirmed post-chemotherapy teratoma and remained low in 90% of patients with either complete response or non-teratoma after chemotherapy. Sensitivity of miR375 was 93% (95% CI: 68-99), specificity 75% (95% CI: 43-95), NPV 90% (95% CI 95%: 57-98), PPV 82% (CI 95%: 63-93) and the AUC of miR375 in the post-chemotherapy setting was 0.93 (95% CI: 0.83-1.0; p < 0.0001).
Conclusions
miR375 is overexpressed and detectable in the plasma of pts with teratoma while its expression is significantly lower in nonseminoma pts without teratoma or in seminoma. The evaluation of miR371/miR375 may be clinically useful to guide therapeutic decisions (surgery or chemotherapy). Larger studies are warranted.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1541 - TERT gene fusions characterize a subset of metastatic Leydig cell tumors
Presenter: Bozo Kruslin
Session: Poster Display session 3
Resources:
Abstract
5389 - Two-weekly accelerated BEP (aBEP) regimen as induction chemotherapy (CT) in intermediate and poor prognosis patients (pts) with nonseminomatous germ cell tumors (NSGCT): final results of phase II trial.
Presenter: Alexey Tryakin
Session: Poster Display session 3
Resources:
Abstract
3585 - Prognosis of anaemia in disseminated testicular germ cell tumours. On behalf of the Spanish Germ Cell Cancer Group (SGCCG)
Presenter: Esmeralda Garcia Torralba
Session: Poster Display session 3
Resources:
Abstract
2254 - The Effects Of Primary Testicular Tumor Localization On Prognosis In Patients With Nonseminomatous Testis Cancer
Presenter: Birol Yildiz
Session: Poster Display session 3
Resources:
Abstract
4505 - Initial Results of a Phase II study of Nivolumab and Ipilimumab in Metastatic Adrenal Tumors.
Presenter: Matthew Campbell
Session: Poster Display session 3
Resources:
Abstract
3369 - NEMIO: a randomized phase II trial evaluating efficacy and safety of dose dense MVAC (ddMVAC) + durvalumab +/- tremelimumab as neoadjuvant treatment in patients with bladder muscle-invasive urothelial carcinoma
Presenter: Constance Thibault
Session: Poster Display session 3
Resources:
Abstract
2075 - KEYNOTE-866: Phase 3 Study of Perioperative Pembrolizumab (pembro) or Placebo (pbo) in Combination With Neoadjuvant Chemotherapy in Cisplatin (cis)-Eligible Patients (pts) With Muscle-Invasive Bladder Cancer (MIBC)
Presenter: Arlene Siefker-Radtke
Session: Poster Display session 3
Resources:
Abstract
4824 - KEYNOTE-905: A Phase 3 Study of Cystectomy Plus Perioperative Pembrolizumab Versus Cystectomy Alone in Cisplatin (cis)-Ineligible Patients (pts) With Muscle-Invasive Bladder Cancer (MIBC)
Presenter: Matthew Galsky
Session: Poster Display session 3
Resources:
Abstract
2253 - Phase 3 LEAP-011 trial: First-Line Pembrolizumab With Lenvatinib in Patients With Advanced Urothelial Carcinoma Ineligible to Receive Platinum-Based Chemotherapy
Presenter: Yohann Loriot
Session: Poster Display session 3
Resources:
Abstract
4310 - PULSE : A Single Arm Trial Assessing The Activity and Safety of Avelumab Immunotherapy Maintenance among Patients With Locally Advanced or Metastatic Squamous Cell Penile Carcinoma (mSCPC).
Presenter: Noemie Gassian
Session: Poster Display session 3
Resources:
Abstract